[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"microbiome-analysis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:microbiome-analysis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,77,123,149,179,230],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100641673","impact-of-ambulatory-physiological-stimulation-of-the-efferent-limb-prior-to-ileostomy-closure-on-colorectal-microbiota-composition-and-histopathological-findings-100641673",false,"NCT07640113","Impact of Ambulatory Physiological Stimulation of the Efferent Limb Prior to Ileostomy Closure on Colorectal Microbiota Composition and Histopathological Findings","The STIMIC Trial: A Multicenter Randomized Control Trial Evaluating the Impact of Ambulatory Physiological Stimulation of the Efferent Limb Prior to Ileostomy Closure on Colorectal Microbiota Composition and Histopathological Findings","STIMIC","Inclusion criteria:\n\n1. Patients 18 yo and older, with a loop ileostomy after colorectal surgery for malignant or benign disease and a barium enema that rules out colorectal anastomotic leak or stenosis.\n2. Patients must be self-sufficient in their stoma care or dispose of assistance by a family member or healthcare provider.\n3. Patients must reside no further than 50km from the hospital and dispose of postoperative home-assistance by a family member or healthcare provider.\n\nExclusion criteria:\n\n1. Patients with a terminal ileostomy or a closed distal limb, inaccesible to preoperative stimulation.\n2. Patients with the diagnosis of inflammatory bowel disease.\n3. Patients incapable of comprehending or signing the informed consent.","ALL","18 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","BACKGROUND Loop ileostomies are a type of stoma frequently used to protect high-risk colorectal anastomoses (surgical reconnection of the intestines), for example following rectal cancer resection. Temporary diversion of intestinal transit does not reduce the risk of anastomotic failure, but it does lower the morbidity and mortality associated with potential pelvic sepsis. Unfortunately, a second surgical procedure is required to restore intestinal continuity, and this carries its own risk of complications, the most common being postoperative ileus (temporary paralysis of bowel motility associated with abdominal distension, absence of bowel movements, nausea, and vomiting), which occurs in up to 20% of cases.\n\nSeveral strategies have been proposed to reduce this problem, including stimulation of the efferent limb of the ileostomy (the part that is connected to the unused colon). This intervention consists of instilling a substance through the efferent limb of the ileostomy into the colon, simulating natural intestinal transit. It emerged as a harmless alternative aimed at reversing changes in the excluded colon in preparation for restoration of intestinal continuity. Several Spanish studies have investigated this technique, concluding that it is safe and significantly reduces the rate of postoperative ileus, thereby shortening hospital stay. Regarding the mechanism by which this intervention may be effective, there are studies investigating the changes that occur during diversion of intestinal transit:\n\n1. Histopathology: reduced muscular contractility and the presence of intestinal villi in the efferent intestinal limb and excluded colon, which improve once intestinal flow is restored.\n2. Microbiome: significant loss of microbiota in the defunctionalized colon, which progressively recovers with natural intestinal transit and reintroduction of a fiber-rich diet.\n\nStructural and microbiota-related changes favor the development of diversion colitis, a condition associated with erratic bowel habits once intestinal transit is restored. In an attempt to reverse this condition, several products have been tested for stimulation of the efferent limb of the ileostomy: probiotics, short chain fatty acids, saline solution with a thickening agent, and the patient's own intestinal contents, a well-tolerated and effective technique, in some cases superior to saline-based alternatives.\n\nOverall, the available evidence is of low quality due to the limited number of patients studied and protocol variability. For this reason, we propose the implementation of a protocol for stimulation of the distal ileostomy limb prior to ileostomy closure, either with saline solution and thickening agent (the most widely described technique in the literature) or physiological stimulation using the patient's own intestinal contents.\n\nThe protocol consists of several sessions in which the instilled volume is progressively increased. This intervention will be performed on an outpatient basis, once daily, during the two weeks prior to surgery.\n\nThis process promotes the onset of bowel movements through the anus, which progressively become more formed and less frequent, approaching a more normal bowel habit. Only minor adverse effects have been described with this technique, including cramp-like abdominal pain in 27.6% of sessions. Recently, a nationwide study confirmed the favorable clinical outcomes following distal ileostomy limb stimulation before ileostomy closure. However, to our knowledge, no studies have evaluated its effect on intestinal microbiota.\n\nHYPOTHESIS Distal limb stimulation of the ileostomy before its closure helps in the recovery of the colorectal microbiome and tissue. This associates with lower postoperative complications, specially postoperative ileus.\n\nOBJECTIVES To gain knowledge regarding changes in intestinal microbiota composition before and after stimulation, in order to better understand recovery of intestinal function following this procedure. We will also analyze outcomes after ileostomy closure following efferent limb stimulation, determining the incidence of postoperative complications, particularly postoperative ileus.\n\nMETHODOLOGY\n\nPatients will be randomly assigned to one of three groups:\n\n1. Control (no intervention other than the usual preoperative protocol)\n2. Stimulation with serum and thickener\n3. Stimulation with own stoma output\n\nSamples will be collected in all patients:\n\n1. Stoma output\n2. Stool, before stimulation, if performed\n3. Stool, after stimulation, if performed\n4. Stool, a month after surgery\n\nFor a group of patients, the ones recruited at Hospital Clínic, rectal biopsies will also be collected before and after stimulation, to compare the effect of the treatment in the colonic tissue. We will collect clinical data during the whole process regarding postoperative complications.",[27,28,29],"Ileostomy Stoma","Stoma Stimulation","Microbiome Analysis",[31,32,33],"efferent limb stimulation","ileostomy closure","colorectal microbiome","NOT_YET_RECRUITING","2026-06-15",{"date":37,"type":38},"2026-06-17","ACTUAL",{"date":40,"type":21},"2026-06",{"date":42,"type":21},"2028-03",{"name":44,"class":45},"Hospital Clinic of Barcelona","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100639378","influence-of-the-gut-microbiome-on-blueberry-polyphenol-metabolites-100639378","NCT07607158","Influence of the Gut Microbiome on Blueberry Polyphenol Metabolites","BlueBIOME","Inclusion Criteria:\n\n* Healthy adults ≥18 years of age\n* Able and willing to provide informed consent\n* Willing and able to adhere to all study procedures and visit requirements\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Pregnant or breastfeeding\n* Presence of chronic diseases, including but not limited to cardiovascular disease, diabetes, cancer, kidney, liver, gastrointestinal, or pancreatic disease\n* Use of medications for chronic diseases that may interfere with study outcomes\n* Any condition known to negatively impact nutrient absorption (e.g., inflammatory bowel disease, celiac disease, gastroparesis)\n* Anemia (hemoglobin \\\u003C13.5 g\u002FdL in men or \\\u003C12.0 g\u002FdL in women)\n* Body mass index (BMI) ≤18.5 kg\u002Fm²\n* Use of antibiotics within the past 2 months\n* Recent blood draw within 1 week prior to study participation\n* Currently participating in another research study involving a diet or exercise intervention\n* Known allergy or contraindication to blueberry products or study procedures\n* Unwilling or unable to comply with study requirements",true,{"count":55,"type":21},125,[24],"The objective of this study is to determine whether inter-individual differences in the gut microbiome influence exposure to blueberry polyphenol metabolites. We will use pharmacokinetics of blueberry polyphenols after an acute blueberry exposure to group individuals into \"metabotypes\", groups of individuals based on similarity in their metabolite profiles. We will then use multi-omic approaches to determine whether the gut microbiome predicts an individual's metabotype.",[29,59],"Metabolomics",[61,62,63,64,65],"Microbiome","Polyphenols","Metabotype","Pharmacokinetics","Metabolites","RECRUITING","2026-05-19",{"date":69,"type":38},"2026-05-26",{"date":71,"type":38},"2026-01-27",{"date":73,"type":21},"2028-01-01",{"name":75,"class":45},"Colorado State University",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":99,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":4},"100628100","probiotic-research-open-label-functional-intervention-and-longitudinal-evaluation-in-healthy-adults-100628100","NCT07457242","Probiotic Research: Open-label Functional Intervention and Longitudinal Evaluation in Healthy Adults","PROFILE","Inclusion Criteria:\n\n* Aged 18 years or older at the time of providing informed consent.\n* In generally good health, with no known medical conditions that could interfere with the aims of the study or participant safety, as judged by self-report and screening questionnaire.\n* No history of significant psychiatric or neurological illness\n* Ability to complete study specific tasks, including:\n* Daily oral intake of a probiotic capsule\n* Self-collection of stool samples\n* Completion of online questionnaires and simple cognitive tasks\n* Able to read, understand, and communicate in English, in order to give informed consent and follow study instructions.\n* Access to the internet and a suitable device (e.g., smartphone, tablet, or computer) for completing online aspects of the study.\n\nExclusion Criteria:\n\n* Participants will be excluded from the study if any of the following criteria apply:\n* Use of any systemic antibiotic or systemic immunosuppressive medication within the past 8 weeks, including but not limited to:\n* β-lactam antibiotics, macrolides, tetracyclines, fluoroquinolones, aminoglycosides, glycopeptides, sulfonamides, antimycobacterial agents, systemic antifungals or antivirals\n* Use of any systemic immunosuppressants within the past 16 weeks, including, but not limited to:\n* Systemic corticosteroids, conventional immunosuppressants, biologic immunomodulators, targeted synthetic immunosuppressants, cytotoxic chemotherapy, or transplant-related immunosuppression.\n* A longer exclusion window is applied for systemic immunosuppressive therapies due to their prolonged and potentially lasting effects on immune function and gut microbial composition compared with systemic antibiotics.\n* Participants who commence systemic antibiotics or immunosuppressive therapy after enrolment will not be withdrawn from safety monitoring but will stop the supplement and will not continue the intervention phase of the study. With participant consent, data collected may still be used.\n* Major gastrointestinal disease or surgery:\n* Any history of significant gastrointestinal disease or surgery that may alter gut microbiome composition, immune function, or nutrient absorption, including but not limited to inflammatory bowel disease (Crohn's disease, ulcerative colitis, indeterminate colitis); coeliac disease or other chronic malabsorptive disorders; chronic liver, biliary, or pancreatic disease; moderate-to-severe or unstable irritable bowel syndrome; gastrointestinal malignancy; chronic gastrointestinal motility disorders; recurrent Clostridioides difficile infection; or any major gastrointestinal surgery such as bowel resection, bariatric surgery, colectomy, ileostomy or colostomy. Prior appendectomy or cholecystectomy alone is not exclusionary.\n* Current pregnancy or development of pregnancy, breastfeeding\n* Known allergy to probiotic or compounding ingredients:\n* Vitamin D3\n* Isomaltooligosaccharide\n* Yeast extract",{"count":85,"type":21},180,[24],"This study is a pre-post, open-label cohort study designed to investigate how a food-grade probiotic supplement affects biological measurements and wellbeing in healthy adults. Participants will take one capsule daily for either 1 month or 6 months.\n\nDuring the study, participants will complete online cognitive tasks and provide blood and stool samples collected during home visits by trained staff. The samples will be analysed to explore changes in gut bacteria and other biological markers.\n\nThis study aims to understand whether the supplement is well tolerated and whether measurable biological changes occur. The study does not involve any experimental drugs or invasive procedures beyond blood sampling and stool collection, and participants will not be asked to change any current prescribed medications or treatments; with eligibility exclusions applying for recent antibiotics or immunosuppressants. The supplement is being studied for research purposes only and is not intended to diagnose, treat, or prevent disease. Participants will be invited to participate in a follow-up visit to assess long-term effects.",[89,90,29,91,92,93,94,95,96,97,98],"Cognition","Multiomics","Metabolome","Proteome","Metagenome","Probiotics Supplement","Gut-brain Axis","Pilot Study","Adult","Sleep",[100,101,61,102,59,103,104,105,106,107,108,109,110,111,112],"Probiotics","Dietary Supplements","Multi-omics","Proteomics","Mitochondrial Function","Cellular Metabolism","Short-Chain Fatty Acids","Bioinformatics","Healthy volunteers","Pilot study","feasibility study","cognitive function","mental health","2026-03-03",{"date":115,"type":38},"2026-03-09",{"date":117,"type":21},"2026-07-01",{"date":119,"type":21},"2027-07-01",{"name":121,"class":122},"OneCarbon","INDUSTRY",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":76},"100589458","comparison-of-microbiome-changes-in-healthy-adults-following-ketone-ester-consumption-100589458","NCT06954675","Comparison of Microbiome Changes in Healthy Adults Following Ketone Ester Consumption","Bacterial Responses to Enteric Alterations After Ketones","BREAK","Inclusion Criteria:\n\n* Subject is male or female, 18 to 40 years of age, inclusive, at Virtual Visit 1.\n* Subject has a self-reported BMI of 18.5 to 39.9 kg\u002Fm2 (inclusive) at Virtual Visit 1.\n* Subject is willing and able to comply with all study procedures including maintenance of habitual dietary intake, consumption of study product at specified intervals, written questionnaires including study log and beverage tolerability questionnaire (KETQ), habitual exercise and medication and supplement use.\n* Subject has an email address and internet access via computer, phone, or other device, and is willing and able to maintain internet access throughout the trial to complete virtual visits via video conference.\n* Subject has no health conditions that would prevent them from fulfilling the study requirements as judged by the Study Clinician on the basis of medical history.\n* Subject understands the study procedures and signs forms providing informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Subject is unable to converse in English or Spanish\n* Subject is unable to provide informed consent due to cognitive impairment or insufficient English or Spanish language comprehension\n* Subject has been hospitalized within 30 days of Virtual Visit 1.\n* Subject has a history or presence of uncontrolled and\u002For clinically active pulmonary, cardiac (e.g. \\>= New York Heart Association class III), hepatic, renal, endocrine (including type 1 diabetes), hematologic, immunologic, neurologic (e.g., Alzheimer's or Parkinson's diseases), psychiatric (including unstable depression and\u002For anxiety disorders) or biliary disorders. Stable chronic disease is not an exclusion criterion unless specified.\n* Subject has a clinically important gastrointestinal condition that would potentially interfere with the evaluation of the study beverage \\[e.g., inflammatory bowel disease, irritable bowel syndrome, chronic constipation, severe constipation (in the opinion of the Study Clinician), history of frequent diarrhea, history of surgery for weight loss, gastroparesis, systemic disease that might affect gut motility according to the Study Clinician, reflux requiring daily medication, history of gastrointestinal ulcers or bleeding, celiac disease, and\u002For clinically important lactose intolerance\\].\n* Subject has a known allergy, intolerance, or sensitivity to any of the ingredients in the study product, including milk protein.\n* Subject is undergoing treatment or active surveillance for cancer, or has been diagnosed with cancer in the prior two years, except for non-melanoma skin cancer.\n* Subject has recently used antibiotics within 60 days of Virtual Visit 1.\n* Subject has extreme dietary habits (e.g., intermittent fasting or time restricted eating, Atkins diet, vegan, very high protein\u002Flow carbohydrate or has used weight-loss medications (including over-the-counter medications and\u002For supplements) or programs within 30 days of Virtual Visit 1.\n* Subject has used medications (over-the-counter or prescription) known to influence gastrointestinal function including, but not limited to, opioids, weight loss medications, antidiarrheals, and antispasmodics) within 30 days of Virtual Visit 1.\n* Subject has used ketone supplements (ketone salts or esters, and medium chain triglycerides \\[MCT\\]) within 30 days of Virtual Visit 1.\n* Subject is a female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period. The method of contraception must be recorded.\n* Subject has a condition the Study Clinician believes would interfere with their ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the subject at undue risk.","40 Years",{"count":133,"type":21},20,[24],"The goal of this observational study is to learn if a ketone ester can improve the content of the gut microbiome. The main questions it aims to answer are:\n\n* Does a ketone ester reduce age-related signatures in the gut microbiome?\n* What changes occur in the gut microbiome after consuming a ketone ester?\n\nParticipants will:\n\n* Take a ketone ester every day for seven (7) days\n* Collect and ship stool samples within seven (7) days before, during, and within seven (7) days after the study period\n* Measure their ketone levels with a urine strip every day after having the drink\n* Answer questions about their typical diet on a normal day\n* Record their symptoms, if any arise",[29],[61,138,139],"Exogenous ketone","Ketone ester","2026-01-22",{"date":142,"type":38},"2026-01-26",{"date":144,"type":38},"2025-11-21",{"date":146,"type":21},"2026-09-30",{"name":148,"class":45},"University of California, San Francisco",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":76},"100470968","augmented-response-of-volatile-biomarkers-in-assessment-of-oesophagogastric-cancer-aroma-1--bioresource-100470968","NCT05412758","Augmented Response of Volatile Biomarkers in Assessment of Oesophagogastric Cancer (AROMA 1 \u002F BIORESOURCE)","Augmented Response of Volatile Biomarkers in Assessment of Oesophagogastric Cancer","AROMA 1 Inclusion Criteria:\n\n1. Aged 18-90years\n2. Oesophageal\u002Fgastric cancer cohort: participants with biopsy proven adenocarcinoma who are treatment naïve\n3. Control cohort: participants with normal or benign upper gastrointestinal disease determined on: • Endoscopy within 1 year • Planned endoscopy\n\nAROMA 1 Exclusion criteria:\n\nPatients with the following characteristics will not be eligible for inclusion in this study:\n\n1. Oesophageal squamous cell carcinoma\n2. Previous oesophageal and gastric resection\n3. Received neoadjuvant chemotherapy for oesophageal or gastric cancer\n4. History of another cancer within three years\n5. Any form of oesophageal dysplasia (control cohort only)\n6. Previously diagnosed with Barrett's oesophagus (control cohort only)\n7. Active infection, on immunosuppressive medications or antibiotic therapy within the last 8 weeks\n8. Participants with co-morbidities preventing breath collection\n9. Allergies to any of the constituents of the nutrient drink including glucose, glycerol, iron sulphate, Maltodextrin (Corn, Potato), Xanthan Gum, Potassium Chloride, tyrosine, phenylalanine, and glutamic acid\n10. Unable or unwilling to provide informed written consent\n11. Pregnant participants\n\nBIORESOURCE inclusion criteria:\n\n1. Aged 18- 90years\n2. Oesophageal\u002Fgastric cancer cohort: participants with biopsy proven adenocarcinoma who are treatment naïve\n3. Oesophageal\u002Fgastric control cohort: participants with normal or benign upper gastrointestinal disease determined on: • Planned endoscopy\n\nBIORESOURCE exclusion criteria:\n\n1. Oesophageal squamous cell carcinoma\n2. Previous oesophageal and gastric resection\n3. Received neoadjuvant chemotherapy for oesophageal or gastric cancer\n4. History of another cancer within five years\n5. Any form of oesophageal dysplasia (oesophageal\u002Fgastric control cohorts only)\n6. Previously diagnosed with Barrett's oesophagus (oesophageal\u002Fgastric control cohorts only)\n7. Active infection, on immunosuppressive medications or antibiotic therapy within the last 8 weeks\n8. Participants with co-morbidities preventing breath collection\n9. Unable or unwilling to provide informed written consent\n10. Pregnant participants","90 Years",{"count":158,"type":21},648,[24],"Cancer of the stomach and oesophagus is among the world's top five cancers. Survival rates are very poor as the disease presents late and early symptoms are non-specific. The study team has developed a non-invasive test for cancers of the stomach and oesophagus based on the detection of volatile organic compounds in exhaled breath. These compounds are known to be produced by both cancers as well as cancer associated bacteria within the gut.\n\nThe proposed innovation is to improve the accuracy of this test by investigating whether simple metabolic substrates can increase the production of these volatile organic compounds by both the tumour and its associated bacteria.",[162,61,163,164,165,166,167,168,29,169],"Volatile Organic Compounds","Microbioata","Breath Analysis","Oesophageal Cancer","Gastric Cancer","Volatalomics","Metabonomics\u002FLipidomics","Transcriptomics","2025-01-29",{"date":172,"type":38},"2025-01-31",{"date":174,"type":38},"2022-02-28",{"date":176,"type":21},"2025-10",{"name":178,"class":45},"Imperial College London",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":191,"conditions":192,"keywords":201,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":76},"100577217","a-randomized-double-blind-study-to-assess-the-effect-of-a-postbiotic-on-oxidative-stress-and-exercise-performance-100577217","NCT06795425","A Randomized, Double-Blind Study to Assess the Effect of a Postbiotic on Oxidative Stress and Exercise Performance","A Randomized, Double-Blinded, Placebo-Controlled, Parallel Study, to Assess the Effect of a Novel Postbiotic Blend on Exercise Induced Oxidative Stress Markers and Exercise Performance","PBE","INCLUSION CRITERIA\n\nTo be eligible for inclusion, the participant must fulfill all of the following criteria:\n\n1. Male or female participants between 18 - 45 years of age\n2. Signed informed consent.\n3. Health, which is defined as currently not being treated for an active cardiac, pulmonary, metabolic, immunological, neurological, respiratory, orthopedic, musculoskeletal, psychiatric, or reproductive disease or disorder. With research team and principal investigator discretion, some ongoing treatments will be permitted if a determination is made that the treatment will not increase risk of study participation and the treatment or illness itself will not confound with desired study outcomes.\n4. Physically active, which is defined as performing aerobic or resistance-based physical exercise between 2 and 5 times per week at a rating of perceived intensity (RPE) of 4 or greater (out of 10)\n5. Body mass index values will range from \\>18.5 to \\\u003C 29.9 kg\u002Fm2 (Inclusive)41 (Weir and Jan 2024).\n6. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, and carry out all study-related procedures.\n\nEXCLUSION CRITERIA\n\nParticipants will be excluded from the study if they meet any of the following criteria:\n\n1. Body mass index \\\u003C18.5 to \\\u003C29.9 kg\u002Fm2 (Inclusive)\n2. Use of antibiotics or probiotics in the previous 3 months\n3. Positive medical history and\u002For is currently being treated for some form of heart or cardiovascular, neurological impairment, disease or condition, immune disorder or disease, thyroid disease, kidney disease, renal failure, regular dialysis, liver disease or other diagnosed hepatic impairment.\n4. Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose \\> 126 mg\u002FdL)\n5. Diagnosed with major affective disorder or other significant psychiatric disorder or disturbance that required hospitalization or home intervention in the prior year.\n6. History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).\n7. Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, bile acid malabsorption, H.pylori infection, small intestine bacterial overgrowth (SIBO), celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea)\n8. Recently prescribed or change in dosage (within the past 6 months) of statin drug (i.e., Lipitor, Livalo, Crestor, Zocor, etc.), hypertension medications (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, Vasodilators, etc.), or psychiatric medications.\n9. Consumption (any dose or amount) of any nicotine-containing product (cigarette, cigar, vaping, etc.)\n10. Participants who are lactating, pregnant or planning to become pregnant.\n11. History of alcohol or substance abuse in the 12 months prior to screening\n12. Receipt or use of an investigational product in another research study within 60 days of beginning the study protocol.\n13. Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data.\n14. Extensive travel (\\>1 month) that will disrupt original outline of the study protocol.\n15. Participant is consuming a biotic product (pre-, pro-, syn-, or post-) or alters their diet resulting in a change in the amount of prebiotic, probiotic, or fermented foods that are consumed while in the study protocol.","45 Years",{"count":189,"type":21},80,[24],"This is a prospective, randomized, placebo controlled, double-blind study to assess the effects of a postbiotic blend on exercise induced oxidative stress markers and exercise performance in healthy adult.",[193,194,195,196,197,198,29,199,200],"Oxidative Stress","Healthy","Exercise-induced Muscle Damage","Exercise-induced Muscle Soreness","Immune Function","Gut Health","Exercise Performance","Exercise Metabolism",[202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220],"oxidative stress","antioxidants","postbiotics","ergogenic aid","exercise performance","muscle damage","recovery","gut microbiome","immune function","sleep quality","anxiety","recreationally active","inflammation","endurance training","fecal microbiota","nutritional supplement","aerobic exercise","biomarkers","clinical trial","2025-01-21",{"date":223,"type":38},"2025-01-28",{"date":225,"type":21},"2025-02-01",{"date":227,"type":21},"2026-01-01",{"name":229,"class":45},"Lindenwood University",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":242,"conditions":243,"keywords":248,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":259,"leadSponsor":261,"locationsCount":263},"100576953","phase-4-impact-of-probiotics-on-gut-microbiome-during-antibiotic-prophylaxis-in-elective-orthopedic-surgery-100576953","NCT06791993","Impact of Probiotics on Gut Microbiome During Antibiotic Prophylaxis in Elective Orthopedic Surgery","Impact of Probiotics Combined with Antibiotic Prophylaxis on Gut Microbiome Balance in Patients Undergoing Elective Orthopedic Surgery, Double-Blinded Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged between 18 and 65 years\n* Scheduled for elective low-risk orthopedic surgery (carpal tunnel release, A1 pulley release, knee arthroscopic surgery).\n\nExclusion Criteria:\n\n* History of infection or antibiotic use within the last 12 weeks.\n* Use of routine probiotics, vitamins, or herbal supplements in the last 4 weeks.\n* Known allergy to beta-lactam or cephalosporin antibiotics.\n* History of autoimmune disease, uncontrolled systemic disease, or chronic inflammatory conditions (e.g., systemic lupus erythematosus, rheumatoid arthritis).\n* History of chronic intestinal diseases such as small intestine bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), or celiac disease.\n* Increased risk of infection due to medical comorbidities or use of immunosuppressive drugs.","65 Years",{"count":239,"type":21},60,[241],"PHASE4","This study aims to evaluate whether probiotics can help maintain a healthy gut microbiome in patients receiving prophylactic antibiotics during elective orthopedic surgery. Antibiotics, while effective in preventing infections, can disrupt the balance of gut bacteria, leading to dysbiosis. The study hypothesizes that the use of probiotics during the perioperative period can prevent or reduce this disruption, supporting gut health and overall well-being. The research seeks to answer whether combining probiotics with routine antibiotic prophylaxis can preserve gut microbiome balance and improve patient outcomes.",[244,245,29,246,247],"Dysbiosis","Gut -microbiota","Probiotic","Antibiotic Prophylaxis",[249,250,251,100,247,252,253,254],"Gut Microbiome","Intestinal Dysbiosis","Surgical Site Infection","Human Milk Oligosaccharides (HMO)","Shotgun Metagenomic Sequencing","Short-Chain Fatty Acids (SCFAs)","2025-01-18",{"date":257,"type":38},"2025-01-24",{"date":225,"type":21},{"date":260,"type":21},"2025-10-01",{"name":262,"class":45},"Acibadem Maslak Hospital",6]